- Home
- BCTX vs FLGC Comparison
BCTX vs FLGC Comparison
Compare BCTX & FLGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- FLGC
- Stock Information
- Founded
- BCTX 2014
- FLGC 2019
- Country
- BCTX Canada
- FLGC United States
- Employees
- BCTX N/A
- FLGC N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- FLGC Biotechnology: Pharmaceutical Preparations
- Sector
- BCTX Health Care
- FLGC Health Care
- Exchange
- BCTX Nasdaq
- FLGC Nasdaq
- Market Cap
- BCTX 16.1M
- FLGC 17.3M
- IPO Year
- BCTX N/A
- FLGC 2021
- Fundamental
- Price
- BCTX $3.21
- FLGC $0.68
- Analyst Decision
- BCTX Strong Buy
- FLGC Strong Buy
- Analyst Count
- BCTX 1
- FLGC 3
- Target Price
- BCTX $32.00
- FLGC $5.00
- AVG Volume (30 Days)
- BCTX 3.7M
- FLGC 287.3K
- Earning Date
- BCTX 06-13-2025
- FLGC 05-20-2025
- Dividend Yield
- BCTX N/A
- FLGC N/A
- EPS Growth
- BCTX N/A
- FLGC N/A
- EPS
- BCTX N/A
- FLGC N/A
- Revenue
- BCTX N/A
- FLGC $59,505,000.00
- Revenue This Year
- BCTX N/A
- FLGC $2.33
- Revenue Next Year
- BCTX N/A
- FLGC N/A
- P/E Ratio
- BCTX N/A
- FLGC N/A
- Revenue Growth
- BCTX N/A
- FLGC N/A
- 52 Week Low
- BCTX $0.35
- FLGC $0.42
- 52 Week High
- BCTX $9.82
- FLGC $2.11
- Technical
- Relative Strength Index (RSI)
- BCTX 37.63
- FLGC 63.07
- Support Level
- BCTX $3.09
- FLGC $0.50
- Resistance Level
- BCTX $9.82
- FLGC $0.75
- Average True Range (ATR)
- BCTX 0.74
- FLGC 0.07
- MACD
- BCTX -0.21
- FLGC 0.02
- Stochastic Oscillator
- BCTX 1.78
- FLGC 74.23
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company generates revenue from United States, Germany, and the United Kingdom. It derives a majority of its revenue from the United States.